All Updates

All Updates

icon
Filter
Funding
Iambic Therapeutics raises USD 50 million in extended Series B funding round
AI Drug Discovery
Jun 18, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
AI Drug Discovery

AI Drug Discovery

Jun 18, 2024

Iambic Therapeutics raises USD 50 million in extended Series B funding round

Funding

  • AI drug discovery company Iambic Therapeutics (formerly Entos) has raised USD 50 million in an extended Series B funding round led by new investors Mubadala Capital and Exor Ventures. Qatar Investment Authority and existing investors Abingworth and Illumina Ventures, among others, also participated.

  • The funding will be used to advance further Iambic's pipeline of clinical and preclinical oncology programs, including IAM1363, a brain-penetrant HER2 inhibitor in Phase I/I billion study, and a potential dual CDK2/4 inhibitor targeting treatment resistance in solid tumors.

  • In a previous Series B funding round in October 2023 , the company raised USD 100 million. The round was co-led by Ascenta Capital and Abingworth, with participation from several investors.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.